Blood Pressure Recall 2019: Another 19 Lots Of Losartan Recalled For Cancer-Causing Impurity

Another Losartan Potassium recall has been issued following two other recalls for blood pressure medication made over the last few weeks. Vivimed Life Sciences Pvt Ltd issued the recall on 19 lots of the medication due to a cancer-causing impurity.

The recall affects Losartan Potassium tablets USP in 25, 50 and 100 mg doses. The medication contains N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) above the allowable level accepted by the U.S. Food & Drug Administration and could cause cancer.

The Losartan Potassium tablets were packaged in 90 and 1000 count bottles with an identifying NDC # of 23155-644-09, 23155-645-09, 23155-645-10, 23155-646-09, and 23155-646-10. A full list of the recalled medication can be viewed here. Labels of the recalled Losartan Potassium tablets can be viewed here.

The recalled blood pressure medication was produced by Vivimed in India and distributed by Heritage Pharmaceuticals to nationwide wholesalers, distributors, retail pharmacies, and mail-order pharmacies. There have been no reports of adverse reactions from the recall to date, the companies said.

Patients that take the recalled blood pressure medication should contact their physician for an alternative treatment plan before they stop taking the recalled Losartan Potassium tablets. Consumers concerned about illness from the recalled medication should speak to their pharmacist or healthcare provider.

Questions about the recall can be directed to Vivimed C/o Inmar at 1-877-861-3811, Monday through Friday from 9 a.m. to 5 p.m. ET.

Losartan Potassium tablets are used for the treatment of hypertension as well as for patients that have hypertensive with left ventricular hypertrophy and nephropathy in Type 2 diabetic patients.